Clinical Trial Update: Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of methylprednisolone, horse anti-thymocyte globulin, cyclosporine, and growth factors (filgrastim and/or pegfil…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• Filgrastim (filgrastim)
• Horse anti-thymocyte globulin (anti-thymocyte globulin (equine))
• METHYLPREDNISOLONE (methylprednisolone)
• Pegfilgrastim (pegfilgrastim)
• Pegfilgrastim biosimilar (pegfilgrastim biosimilar)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Aplastic Anemia, de Novo Myelodysplastic Syndrome | Phase 2 | Status: RECRUITING